论文部分内容阅读
糖尿病视网膜病变的成因至今未明,也无满意的治疗方法。治疗原则可分为内科全身疗法和视网膜病变本身的治疗,后者又分为药物、物理及外科疗法。从内科角度而言,即为内科全身药物疗法和视网膜病变的药物疗法。值得提出的是,最近醛糖还原酶(AR)抑制剂异军突起,在防治糖尿病视网膜病变方面引起越来越多的关注。一、糖尿病视网膜病变的发病与自然经过糖尿病视网膜病变的进展与糖尿病患者的性别、年龄及患病时间有关。其发病率随年龄增长而增高,男性在40岁以前,女性在40岁以后
The cause of diabetic retinopathy is still unknown and there is no satisfactory treatment. Therapeutic principles can be divided into medical systemic therapy and retinopathy itself treatment, which is divided into drug, physical and surgical therapy. From a medical point of view, it is a medical therapy of systemic medical therapy and retinopathy. It is worth mentioning that the recent sudden emergence of aldose reductase (AR) inhibitors has drawn more and more attention in the prevention and treatment of diabetic retinopathy. First, the incidence of diabetic retinopathy and natural progression of diabetic retinopathy and diabetes, the gender, age and prevalence of time-related. The incidence increases with age, men before the age of 40, women after the age of 40